TYRA BIOSCIENCES
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment o... ptions. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra’s lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.
TYRA BIOSCIENCES
Social Links:
Industry:
Biotechnology Life Science Oncology Therapeutics
Founded:
2018-01-01
Address:
Carlsbad, California, United States
Country:
United States
Website Url:
http://www.tyra.bio
Total Employee:
11+
Status:
Active
Total Funding:
356 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon WordPress Content Delivery Network LetsEncrypt SSL By Default Mobile Non Scaleable Content HSTS
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
5AM Ventures
5AM Ventures investment in Post-IPO Equity - Tyra Biosciences
Nextech Invest
Nextech Invest investment in Post-IPO Equity - Tyra Biosciences
OrbiMed
OrbiMed investment in Post-IPO Equity - Tyra Biosciences
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Tyra Biosciences
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Tyra Biosciences
BVF Partners
BVF Partners investment in Post-IPO Equity - Tyra Biosciences
Alta Partners
Alta Partners investment in Series B - Tyra Biosciences
Canaan Partners
Canaan Partners investment in Series B - Tyra Biosciences
RA Capital Management
RA Capital Management investment in Series B - Tyra Biosciences
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Tyra Biosciences
Official Site Inspections
http://www.tyra.bio Semrush global rank: 4.96 M Semrush visits lastest month: 1.71 K
- Host name: 89.0.153.160.host.secureserver.net
- IP address: 160.153.0.89
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Tyra Biosciences"
Our People | Tyra Biosciences
He was a founding board member of the Kauffman Fellows Program and is on the board of BIO (Biotechnology Innovation Organization). Before joining Alta, Bob was a Senior Advisor for the …See details»
Tyra Biosciences - Crunchbase Company Profile
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.See details»
Tyra Biosciences, Inc. (TYRA) Company Profile & Facts - Yahoo …
See the company profile for Tyra Biosciences, Inc. (TYRA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Board of Directors | Tyra Biosciences, Inc.
Prior to co-founding Tyra, Todd co-founded Sienna Biopharmaceuticals, Inc. (SNNA) a clinical-stage biopharmaceutical company where he was Chief Executive Officer and a member of the board of directors. ... He was a …See details»
Team Members | Tyra Biosciences
Michael Bober VP, Clinical Development & Medical Affairs. Gary Price VP, Quality. Katherine Hogg Call ClinicalSee details»
Tyra Biosciences, Inc. | SEC Filing
Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90240B106 (CUSIP Number) Josh La Grange. Fried, Frank, Harris, …See details»
Tyra Biosciences, Inc. | Investor Relations
Oct 23, 2024 Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in …See details»
Tyra Bio Investor Relations - Overview
Nov 13, 2024 Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in …See details»
Robert More | Board Member | Tyra Biosciences, Inc.
Bio Details. Robert More Board Member. Robert More is a Managing Director at Alta Partners, a healthcare focused venture capital firm. ... Vir Biotechnology (NASDAQ:VIR). He was a …See details»
Robert More | Tyra Biosciences
He was a founding board member of the Kauffman Fellows Program and is on the board of BIO (Biotechnology Innovation Organization). Before joining Alta, Bob was a Senior Advisor for the …See details»
Tyra Biosciences, Inc. (TYRA) - Yahoo Finance Canada
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers …See details»
Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History ...
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET PR Newswire • last monthSee details»
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 …
Mar 19, 2024 Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in …See details»
Presentations | Tyra Biosciences, Inc.
Oct 26, 2022 Interim clinical data with TYRA-300 from SURF301 3.3 MB. October 24, 2024. ENA PK/PD 1.6 MB. ENA TiP 165.2 KB. September 26, 2024. ASBMR 2024 2.5 MB. …See details»
News & Press | Tyra Biosciences
Mar 31, 2021 Tyra Biosciences raises $106M in Series B financing to advance novel pipeline of therapies targeting acquired resistance in oncology Mar 31, 2021 – Financing led by Nextech …See details»
Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History ...
The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; …See details»
Tyra Biosciences Inc (TYRA) Stock Price & News - Google Finance
Get the latest Tyra Biosciences Inc (TYRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.See details»
Our Approach | Tyra Biosciences
A proprietary in-house discovery platform enables us to see the real-world interaction between drug and target in rapid, sequential, structural SNÅPshots. With each SNÅP, we bring speed, …See details»
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 …
Mar 3, 2022 TYRA remains on track to submit an IND with the U.S. FDA for TYRA-300 in mid-2022 and for TYRA-200 in the second half of 2022. Strengthened Clinical Team with Key Hire. …See details»